# Demonstration of an Anti-allergic Effect in Subjects Treated With Callergin Nasal Spray in Comparison to Untreated Subjects and Subjects Treated With Vis Alpin® Alpensalz Nasal Spray, All Suffering From Grass Pollen Induced Rhinitis/Rhinoconjunctivitis

> **NCT04531358** · NA · COMPLETED · sponsor: **Marinomed Biotech AG** · enrollment: 42 (actual)

## Conditions studied

- Allergic Rhinitis
- Allergic Rhinoconjunctivitis

## Interventions

- **DEVICE:** nasal spray
- **OTHER:** no treatment

## Key facts

- **NCT ID:** NCT04531358
- **Lead sponsor:** Marinomed Biotech AG
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-04
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04531358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04531358, "Demonstration of an Anti-allergic Effect in Subjects Treated With Callergin Nasal Spray in Comparison to Untreated Subjects and Subjects Treated With Vis Alpin® Alpensalz Nasal Spray, All Suffering From Grass Pollen Induced Rhinitis/Rhinoconjunctivitis". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04531358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*